(Q35194346)

7 August 2017

1 reference

title

Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis (English)

1 reference

juvenile rheumatoid arthritis

7 August 2017

main subject

1 reference

0 references

Roy Fleischmann

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

Expert Opinion on Drug Safety

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

347-365

1 reference

Epidemiology of rheumatoid arthritis: update

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

What happens to patients with rheumatoid arthritis? The long-term outcome of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Guidelines for the management of rheumatoid arthritis: 2002 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Salazopyrin in the Treatment of Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Salazopyrin in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Methotrexate in refractory rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Resolve: methotrexate is the drug of choice after NSAIDs in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Anti-cytokine therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Interleukin-11: a new cytokine critical for osteoclast development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Role of cytokines in inflammatory synovitis. The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Sulfasalazine. Adverse effects and desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Rheumatoid arthritis and cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.4.347

21 January 2018

Identifiers

DOI

10.1517/14740338.2.4.347

1 reference

7 August 2017

1 reference